5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
Vamsidhar Velcheti, Pragya Rai, Yu-Han Kao, Diana Chirovsky, Ana T. Nunes, Stephen V. Liu
Topics & Concepts
MedicinePembrolizumabOncologyInternal medicineLung cancerPD-L1Intensive care medicineCancerImmunotherapyCancer Immunotherapy and BiomarkersEsophageal Cancer Research and TreatmentLung Cancer Diagnosis and Treatment